As a drug discovery company, CanBas explains its cancer drug research and development status, clinical data, future trial plans, and progress in the development pipeline. The briefing centers on CBP501 clinical Phase 2 data, the potential of three-drug combination therapy, and the clinical progress of each agent and future trial plans.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4575","jir_company_name":"CanBas Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4575-20260819-01.pdf","jir_short_summary":"As a drug discovery company, CanBas explains its cancer drug research and development status, clinical data, future trial plans, and progress in the development pipeline. The briefing centers on CBP501 clinical Phase 2 data, the potential of three-drug combination therapy, and the clinical progress of each agent and future trial plans.","jir_summary":"### Section heading\nThis document is an earnings briefing that explains CanBas's drug discovery platform and ongoing pipeline, focusing on CBP501 clinical trajectory, potential combinations with other drugs, the efficacy evaluation of Phase 2 clinical data, and future clinical plans. The document does not appear to include data on immune-checkpoint antibody combination effects, trial progress schedules, or information on partnerships or capital policy.\n\n### Section 2 heading\nDetailed discussion of the efficacy of the three-drug combination therapy centered on CBP501, current clinical data, promising results from the Phase 2 trial, and future trial plans (progress of Phase 1\/2, start timing, target patient groups, etc.). Also presents views on survival and efficacy metrics for combinations with agents such as cisplatin and immune-checkpoint antibodies.","jir_financial_highlights":"Sales: Unknown (Unknown)\nClinical development expenses: Unknown (Unknown)\nCBP501 Clinical Phase 2 trial results: Unknown (Unknown)","jir_category":"","jir_hashtags":"#CanBas, #DrugDiscoveryPlatform, #ClinicalData","jir_key_figures":"CBP501: Phase 2 clinical data (prospects, survival, etc.)\nAssessment of the efficacy of CBP501's triple-drug therapy\nCurrent clinical data and future trial plans (start timing, target patients, etc.)","jir_meta_title":"\u3010CanBas\u3011Progress on CBP501-focused Phase 2 and future trial plans | Fiscal Year 2026 June","jir_meta_description":"Details on CanBas's CBP501-focused clinical data, the promise of triple-drug therapy, current Phase 2 status and future plans, and development roadmap for combinations with immunotherapy.","jir_og_title":"CanBas | Phase 2 data for CBP501 and future plans","jir_og_description":"IR material describing clinical data centered on CBP501 and the potential of triple-drug therapy, with future trial plans.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":58229,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-105315","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n